The study goal is to compare the management of increased intra-cranial pressure (ICP) using 3% hypertonic saline vs. mannitol (given in same osmolar loads). Primary hypothesis: 1\. Hypertonic saline will be non-inferior to mannitol in decreasing elevated ICP. Secondary hypotheses: 1. Hypertonic saline therapy will result with fewer complications than mannitol 2. ICP reduction duration will be longer using hypertonic saline when compared with mannitol
There is growing evidence in the literature indicating that ICP and Cerebral Perfusion Pressure measurements may not be sufficient in the management of elevated ICP. Based on this evidence, monitoring of partial brain tissue oxygenation has gain acceptance among neurosurgeons and neurointensivists, and has become a standard of care monitor in some centers across the country. There is, however, insufficient information in the literature describing the effects of hyperosmolar medications on regional brain tissue oxygenation. We intend to undertake this non-inferiority, prospective, randomized double-blind study to answer very important clinical questions not yet answered in the literature: Will hypertonic saline therapy, given at equiosmolar load, be non-inferior to mannitol in reducing elevated ICP?
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
3% hypertonic saline, dosed by ideal patient weight
Mannitol 20% intravenous solution, dosed by patient's ideal body weight
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Percent reduction of ICP from baseline
Time frame: 30 minutes from completion of medication administration
Time from study drug administration completion to ICP < 25 mmHg
Time frame: First 72 hours
Cumulative duration of ICP below 25 mmHg
Time frame: First 24 hours
Cumulative duration of ICP below 25 mmHg
Time frame: First 72 hours
Cumulative duration of cerebral perfusion pressure (CPP) above 60 mmHg
Time frame: First 24 hours
Cumulative duration of cerebral perfusion pressure (CPP) above 60 mmHg
Time frame: First 72 hours
Cumulative duration of regional oxygen partial pressure (pbtO2) > 20%
Time frame: two hours following each dose administration during the first 24 hours
Total dose of medications given
Time frame: First 24 hours; also over 3 days
Frequency of treatment failure
Treatment failure defined as ICP \> 30 mmHg for \> 30 minutes
Time frame: First 72 hours
Frequency of rebound intracranial hypertension
Rebound intracranial hypertension defined as ICP \> 25 mmHg for more than 10 minutes following ICP stabilization
Time frame: First 72 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Frequency of composite Major Adverse Events
1. acute kidney injury as defined by an increase in creatinine x 2 or GFR decrease \> 50% or urine output \< 0.5 ml/kg/h for 12 hours, compared to baseline, as per RIFLE criteria 2. hypotensive episodes (SBP \< 90 mmHg for more than 10 minutes) 3. hemodynamic instability as measured by decrease of cardiac output by more than 15% within two hours following medication administration 4. pulmonary edema as defined by ELWI I\> 10
Time frame: 3 days
Difference in inflammatory response
Determined by analysis of cytokine and inflammatory biomarkers.
Time frame: Regular intervals over first 3 days
Difference in average pre-discharge stroke scale score
Time frame: hospital discharge (or 30 days if not discharged)